Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization
Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback
Regulatory filings in other territories are ongoing and remain on track
Ad hoc announcement pursuant to Art. 53 LR
